title: [Clinical, laboratory and therapeutics aspects of Sheehan's syndrome].
abstract: Sheehan's syndrome is characterized by hypopituitarism that occurs as a result of ischemic pituitary necrosis due to severe postpartum hemorrhage. Nowadays it is not usually seen in developed countries because of the improvements in obstetric care. However, in developing countries it is still frequent and probably one of the most common causes of hypopituitarism. Most patients usually present it months to years later, with a history of failure of postpartum lactation, failure to resume menses and other signs of panhypopituitarism. In mild forms of the disease, patients may remain undetected and do not receive treatment for many years. Early diagnosis and appropriate treatment are important to reduce the morbimortality of the patients with Sheehan's syndrome. The aim of this review is to describe clinical, laboratory and therapeutic aspects of Sheehan's syndrome, including our experience in the replacement of recombinant GH in these patients.
authors.affiliation: Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brazil. wellbs@terra.com.br
authors.forename: Débora Vieira
authors.initials: DV
authors.lastname: Soares
authors.forename: Flávia Lúcia
authors.initials: FL
authors.lastname: Conceição
authors.forename: Mário
authors.initials: M
authors.lastname: Vaisman
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology; D003937:Diagnosis, Differential; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D019382:Human Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000175:diagnosis* / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone